944718-19-8

Basic information

• Product Name: 3-Bromo-5-(1-pyrrolidinyl)-pyridine
• Synonyms: 3-Bromo-5-(1-pyrrolidinyl)-pyridine;3-bromo-5-(pyrrolidin-1-yl)pyridine;3-Bromo-5-pyrrolidinopyridine;3-Bromo-5-(pyrrolidin-1-yl)
• CAS NO: 944718-19-8
• Molecular Formula: C9H11BrN2
• Molecular Weight: 227.10104
• Mol File: 944718-19-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 90-91 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 318.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.480±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.90±0.22(Predicted)
• CAS DataBase Reference: 3-Bromo-5-(1-pyrrolidinyl)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-(1-pyrrolidinyl)-pyridine(944718-19-8)
• EPA Substance Registry System: 3-Bromo-5-(1-pyrrolidinyl)-pyridine(944718-19-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 944718-19-8(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-(1-pyrrolidinyl)-pyridine, also referred to by its IUPAC name 5-Bromo-3-(1-pyrrolidinyl)pyridine, is an organic chemical compound that is part of the Pyridines, Pyrrolidines and related categories of chemicals. It is composed of a pyridine ring substituted by a bromine atom and a pyrrolidine ring. The exact molecular weight of the compound is 216.09 g/mol. As a specialty chemical, it is primarily used in various research and development applications, playing a role in the synthesis of more complex chemical compounds. The handling and use of this chemical should be done under controlled conditions by trained professionals, as it may have potential health hazards.

Upstream product

• 123-75-1 pyrrolidine 
• 625-92-3 3,5-dibromopyridine 
• 233770-01-9 3-bromo-5-iodopyridine 

Downstream Products

• 1312593-93-3 N-{6-methyl-2-(1H-pyrazol-4-yl)-3-[5-(1-pyrrolidinyl)-3-pyridinyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide 
• 1312593-88-6 3-chloro-N-{6-methyl-2-(1H-pyrazol-4-yl)-3-[5-(1-pyrrolidinyl)-3-pyridinyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide 
• 1201644-49-6 3-(pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Relevant articles and documents

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

NOVEL COMPOUNDS

The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase II enzyme.

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE

A compound which is a pyrrolopyrimidine of formula (I) wherein: R1 is selected from R9 and halogen; R2 is NR6R7; R3 is selected from H, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nAr; R4 is selected from H, C1-C6 alkyl and -(CH2)? Ar; or R3 and R4 form, together with the N and C atoms to which they are attached, a fused five-, six-, seven- or eight-membered N-containing saturated ring which is unsubstituted or substituted; R5 is selected from CN, C02R9,C(O)NR10R11, -(CH2)nOH, -(CH2)nR10Rn, -C=CH, -C(S)NR10R11, -C(NH2)=NOR9, -C(R9)=NOR9, -C(NH2)NH, -C(O)R9 and an unsaturated 5- or 6-membered heterocyclic group which contains 1, 2 or 3 heteroatoms selected from N, O and S and which is unsubstituted or substituted; R6 and R7, which are the same or different, are selected from C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nX and -(CH2)nAr; or R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated five-, six-, seven- or eight-membered heterocyclic group which contains one nitrogen atom and 0 or from 1 to 3 additional heteroatoms selected from N, O and S, which is unsubstituted or substituted and which optionally contains one or two bridgehead atoms; R10and R11,which are the same or different, are selected from H, C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nC3-C10 cycloalkyl and -(CH2)nAr; or R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated five or six membered heterocyclic group which contains a nitrogen atom and 0 or from to 3 additional heteroatoms selected from O, S and N, which is unsubstituted or substituted and which is optionally fused to a benzene ring which is unsubstituted or substituted; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of from 1 to 6; X is selected from -CN, -C02R9 and -NR10R11; R9 is the same or different when more than one is present within a given substituent group and is selected from -H, -QAr, -(CH2) nAr, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nC3-C10cycloalkyl, wherein the cycloalkyl moiety is optionally fused to a benzene ring which is unsubstituted or substituted; Q is C2-C6 alkenylene or alkynylene; and Ar is an unsaturated C6-C10 membered carbocyclic group or an unsaturated 5-11 membered heterocyclic group, which groups are unsubstituted or substituted; or a pharmaceutically acceptable salt thereof. These compounds have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.